Immix Biopharma Inc
NASDAQ:IMMX

  • LAST PRICE
    1.9800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.8100/ 5
  • Ask / Lots
    2.6000/ 3
  • Open / Previous Close
    0.0000 / 1.9800
  • Day Range
    ---
  • 52 Week Range
    1.5500
    7.7500
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
IMMX
Immix Biopharma Inc
52.3M
-2.1x
---
MURA
Mural Oncology PLC
53.1M
-0.3x
---
VTVT
vTv Therapeutics Inc
53.2M
-2.0x
---
OKYO
OKYO Pharma Ltd
40.2M
-0.1x
---
RPHM
Reneo Pharmaceuticals Inc
50.5M
-0.7x
---
LTRN
Lantern Pharma Inc
50.2M
-2.9x
---
As of 2024-07-01

Company Information

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Contact Information

Headquarters
11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
Phone
310-651-8041
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Ilya Rachman
Scientific Co-Founder
Vladimir Torchilin
Chief Financial Officer, Director
Gabriel Morris
Head - Chemistry, Manufacturing, and Control
Nandan Oza
Acting Chief Medical Officer, Head - Clinical Development
Graham Ross

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$52.3M
Revenue (TTM)
$0.00
Shares Outstanding
26.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.93
Book Value
$0.82
P/E Ratio
-2.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.